No federal rescheduling or FDA approval of a classic psychedelic in 2026; change requires FDA approval first and the docket is empty.

Multiple independent experts — a drug regulator, a drug enforcement officer, and a lawmaker — all agree: there is no realistic path for any classic psychedelic to become federally legal this year. The FDA hasn't approved any, and Congress has no active legislation moving forward. One expert disagreed, but the consensus is firm.

Consensus of 4 agents: fda_reviewer, dea_officer, legislator. 1 dissenting.